Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors.


Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2022
Historique:
entrez: 20 7 2022
pubmed: 21 7 2022
medline: 22 7 2022
Statut: ppublish

Résumé

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs. In the discovery of PCSK9/LDLR (low-density lipoprotein receptor) protein-protein interaction (PPI) impairing small molecules, a total of 47 phenylbenzo[d][1,3] dioxole-based compounds were designed and synthesised. The result revealed that the 4-chlorobenzyl substitution in the amino group is important for the PPI disrupting activity. In the hepatocyte-based functional tests, active compounds such as

Identifiants

pubmed: 35854672
doi: 10.1080/14756366.2022.2101645
pmc: PMC9307114
doi:

Substances chimiques

Dioxoles 0
PCSK9 Inhibitors 0
PCSK9 protein, human EC 3.4.21.-
Proprotein Convertase 9 EC 3.4.21.-
Subtilisins EC 3.4.21.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2017-2035

Références

Eur J Med Chem. 2019 Jan 15;162:212-233
pubmed: 30448414
Bioorg Med Chem. 2020 Mar 15;28(6):115344
pubmed: 32051094
Molecules. 2020 Jan 01;25(1):
pubmed: 31906305
J Enzyme Inhib Med Chem. 2021 Dec;36(1):707-718
pubmed: 33663315
J Lipid Res. 2007 Jul;48(7):1488-98
pubmed: 17449864
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
Am J Epidemiol. 2004 Sep 1;160(5):421-9
pubmed: 15321838
Curr Top Med Chem. 2019;19(20):1790-1817
pubmed: 31400268
Cochrane Database Syst Rev. 2017 Apr 28;4:CD011748
pubmed: 28453187
ACS Med Chem Lett. 2018 Dec 03;10(4):425-430
pubmed: 30996774
Environ Pollut. 2021 Dec 1;290:118112
pubmed: 34500398
J Med Chem. 2019 Jul 11;62(13):6163-6174
pubmed: 31260298
J Am Chem Soc. 2018 Mar 7;140(9):3242-3249
pubmed: 29378408
Ann Intern Med. 2015 Jul 7;163(1):40-51
pubmed: 25915661
Front Physiol. 2020 Nov 16;11:595819
pubmed: 33304274
Yonsei Med J. 2015 Sep;56(5):1251-7
pubmed: 26256967
N Engl J Med. 2015 Apr 16;372(16):1489-99
pubmed: 25773378
Org Biomol Chem. 2016 Oct 18;14(41):9736-9740
pubmed: 27722650
Nat Rev Cardiol. 2019 Mar;16(3):155-165
pubmed: 30420622
J Clin Lipidol. 2016 May-Jun;10(3):472-89
pubmed: 27206934
Expert Opin Ther Targets. 2009 Jan;13(1):19-28
pubmed: 19063703

Auteurs

Fahui Li (F)

Department of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.

Lihui Zhang (L)

School of Stomatology, Weifang Medical University, Weifang, China.

Jinhong Feng (J)

Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.

Lei Zhang (L)

Department of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH